Background: A clinical large anterior vessel occlusion (LAVO)-prediction scale could reduce treatment delays by allocating intra-arterial thrombectomy (IAT)-eligible patients directly to a comprehensive stroke center.
Introduction
Time is the most crucial factor limiting clinical effectiveness of intra-arterial thrombectomy (IAT) in stroke due to large anterior vessel occlusion (LAVO). 1, 2 With every minute of delay, 4.2 days of disability-free life are lost, and chances of undergoing IAT are reduced by 2.5%. 3, 4 A clinical scale to identify LAVO in the prehospital Emergency Medical Services (EMS) setting could reduce treatment delays by allocating IAT-eligible patients directly to a comprehensive stroke center (CSC). 5, 6 Ideally, such a scale should be straightforward, widely applicable, have high interrater reliability and high accuracy in terms of LAVO-prediction. 7 Various scales have been designed, but it is unclear which performs best in clinical practice. [8] [9] [10] [11] [12] [13] [14] [15] The National Institutes of Health Stroke Score (NIHSS) retains the highest overall accuracy predicting LAVO, 16, 17 but is too extensive for EMS personnel. The Face-arm-speech-time (FAST) score is widely used by EMS personnel but was primarily developed to distinguish stroke from non-stroke rather than stroke subtype. 18 LAVO-prediction scales were compared before, but never systematically, and in different datasets with radiological endpoints not reflecting current clinical practice. 14, 19, 20 Patient characteristics may improve a LAVOprediction model but were not included in previous scales. 21, 22 Aims We aimed to (i) systematically identify published LAVO-prediction scales designed for prehospital use, (ii) assess these scales in terms of feasibility, (iii) assess predictive value in a large, multicenter, prospective dataset with IAT-eligible LAVO as a well-defined radiological outcome measure, (iv) compare these scales to NIHSS and FAST, and finally, (v) develop a prediction model assessing both NIHSS items and patient characteristics associated with LAVO.
Methods

Systematic literature search
A computerized literature search was performed in the following databases: MEDLINE, EMBASE, EMCARE and Web of Science from October 1991 to June 2017 using the following search terms: ''stroke,'' ''cerebrovascular accident,'' ''scales,'' ''scores,'' ''large vessel occlusion,'' ''large artery occlusion,'' ''Emergency Medical Services,'' ''prehospital'' and ''triage.'' Two reviewers (GTK and TTMN) independently screened titles and abstracts for eligibility. Full-text versions were obtained from all studies that were considered to be potentially relevant by one or both reviewers. After a first selection, bibliographies of all relevant studies were searched manually for additional studies and this method of crosschecking was continued until no further publications were found. Authors of relevant articles were contacted for supplementary information.
Cohort studies were reviewed with the STROBE (Strengthening the Reporting of OBservational studies in Epidemiology) statement and had to comply with the following inclusion criteria: (1) original data report on an inception cohort or a clinical trial; (2) a clinical score had to be assessed within 6 h from stroke onset; (3) it had to be clear from the paper at what moment and by whom (e.g. EMS personnel, neurologist) a clinical score was assessed; (4) assessment of LAVO had to be done with either CT angiography (CTA), magnetic resonance angiography, or digital subtraction angiography; (5) data available on the performance of clinical score(s) used had to be expressed as: area under the receiver operating characteristics curve (AUROC), sensitivity/specificity or likelihood ratio, and (6) the clinical score had to be retrievable from NIHSS. Because studies had to fulfill these strict inclusion criteria, no further formal quality assessment was undertaken.
We estimated and/or retrieved the following characteristics from identified studies: feasibility for EMS use, interrater reliability and external validity (i.e. applicability to the unselected population of suspected acute stroke patients).
Validation cohort
To assess validity, we used the Dutch acute Stroke study (DUST) cohort. 23 DUST is a multicenter, prospective, observational cohort study conducted in six university and eight non-university hospitals in the Netherlands. From May 2009 to August 2013, consecutive patients >18 years presented at the emergency department with a suspicion of acute (<9 h) ischemic stroke (based on clinical assessment and non-contrast CT (NCCT) imaging) and NIHSS >1 and/or considered eligible for intravenous thrombolysis (IVT) were included. All patients received CTA within 9 h after symptom onset as part of the CT stroke workup including NCCT, CT perfusion and CTA. The DUST imaging protocol has been described before. 24 A2-segment), intracranial carotid artery (ICA) or tandem (ICA plus MCA) occlusion. 25 Patients with incomplete admission NIHSS were excluded from analyses related to validation of existing scales, since NIHSS was required to reconstruct these.
Descriptive statistics were used to determine baseline characteristics of the validation cohort. Categorical variables were compared with the 2 test and presented as number (percentage). Continuous variables are compared using the t test or Mann-Whitney U test, and are presented as mean AE standard deviation or median (interquartile range, IQR) if appropriate.
To assess predictive value, we computed AUROC and respective 95% confidence intervals (CIs) per identified LAVO-prediction scale, and for the NIHSS and FAST score.
Having data from 14 sites participating in DUST, we performed external validation by excluding one site at a time (cross-validation) for every scale. This is an important advantage, because external validation gives a better indication of the generalization error. We performed all pairwise comparisons of the cross-validated AUROCs of the various scales using the DeLong's test. 26 For the development of a new prediction model, we did not exclude patients with NIHSS items that could not be assessed since this reflects clinical practice. In addition, we introduced (combinations of) patient characteristics into the model that we considered to be predictive of LAVO provided that these also differed on baseline between LAVO and non-LAVO patients. These include: history of atrial fibrillation (AF), AF without the use of anticoagulation, and AF without diabetes mellitus and/or hyperlipidemia.
Group lasso regression analysis was used to reveal (a combination of) NIHSS items and patient characteristics yielding the highest predictive value for LAVO. 27 The lasso is a popular method for penalized regression and classification that also performs variable selection. 28 The group lasso is a variant where the user can specify groups of variables (e.g. all variables within one NIHSS item) that are either all in or all out of the model. 29 We used the R package ''grpreg'' with default settings to fit the group lasso. 30 In addition, a decision tree algorithm and diagram based on dichotomized NIHSS items ((1) 'yes/present/ abnormal', or (0) 'no/absent/normal') was developed. A decision tree works by consecutively assessing the item with the highest predictive value in the (remaining) cohort, as such leading to a minimum amount of items to be assessed to reach an outcome (i.e. LAVO or non-LAVO), with the highest possible predictive value. Cross-validation (as described before) will determine the number of knots in the decision tree. The decision tree was fitted using the R-package ''rpart'' using default settings. In particular, this means that the default priors are proportional to the data counts, the losses default to 1, and the split defaults to the Gini index.
Statistical analysis was performed using SPSS software (version 23, IBM, New York, USA), and R software (version 3.4.1).
Results
Systematic literature search
The MEDLINE search yielded 185 citations, the EMBASE search 263 citations, the EMCARE search 58 citations, and the Web of Science search 163 citations. After removal of duplicates, 522 records remained; 446 records were excluded based on title and abstract; 28 additional relevant studies were found by searching the bibliographies. Screening reference lists and a search of the Science Citation Index yielded 12 additional studies. One-hundred-and-sixteen citations remained for full text assessment. A total of seven clinical scales meeting pre-defined criteria were identified (see Figure 1 ). Clinical scale characteristics and methods of validation are shown in Supplementary Material I. Except for the RACE scale, all validations were performed retrospectively and/or in-hospital and validation cohorts ranged between 62 and 3505 patients. Generally, patients with intracerebral hemorrhage (ICH) were excluded. Definition of LAVO varied substantially between studies (ranging from 'MCA occlusion' to 'anterior or posterior circulation occlusion'), and LAVO-rate ranged between 21 and 73%.
Validation cohort
A total of 1393 patients were included in DUST. Of these, 59 (4%) were excluded because of incomplete NIHSS and 18 (1%) because CTA was of insufficient diagnostic quality to assess LAVO. This left 1316 patients for analysis.
LAVO was present in 471 patients (35.8%). Demographic details of the validation cohort, stratified by presence of LAVO, are presented in Table 1 
Comparison of clinical scales
The FAST-ED (AUROC 0.83, 95% CI 0.80-0.85), RACE scale (AUROC 0.82, 95% CI 0.79-0.84) and NIHSS (AUROC 0.81, 95% CI 0.79-0.84) showed the highest AUROC for detecting LAVO in comparison with other scales (p < 0.01). FAST-ED showed a comparable AUROC to RACE but a significantly higher AUROC than NIHSS (p < 0.01). The FAST score showed the lowest specificity, and the 3I-SS scale showed the lowest sensitivity (see Figure 2 and Table 2 ).
Group lasso LAVO-prediction model
Group lasso analysis showed a prediction model containing a combination of the following NIHSS items (AUROC 0.84, 95% CI 0.81-0.87): (1) level of consciousness (LOC) questions, (2) gaze, (3) visual fields, (4) facial asymmetry, (5) arm motor function, (6) aphasia, and (7) extinction/inattention. Whereas AF was more prevalent in LAVO-patients, it did not contribute to the prediction model as a separate variable or in combination with other patient characteristics as outlined before. 0.76 (95% CI 0.68-0.83). 'Gaze', the item with the highest predictive value for LAVO in our cohort, is the first item to be assessed. For both the group of patients with an abnormal gaze (27%, left side of the diagram) as for the group of patients with a normal gaze (73%, right side of diagram), the following item with the highest predictive value for LAVO is determined. For both subgroups, this item is 'facial asymmetry'. Assessment of this second item leads directly to an outcome (i.e. LAVO or non-LAVO) in 61% of all patients (scoring (a) gaze 'yes' plus facial asymmetry 'yes', (b) gaze 'yes' plus facial asymmetry 'no', or (c) gaze 'no' plus facial asymmetry 'no'). Only for the remaining 39% of patients, the full 4-item decision tree (adding 'LOC questions', followed by 'LOC commands' or 'extinction/inattention') has to be completed (see Figure 3 and Table 3 ).
Decision tree
Discussion
Our systematic search revealed seven LAVO-prediction scales designed for use in the prehospital phase. However, the majority was retrospectively validated in (small) monocenter cohorts in an in-hospital setting, making it difficult to determine which scale outperforms the other in prehospital clinical practice. In our large multicenter validation cohort, we found that FAST-ED and RACE had the highest AUROC for prediction of LAVO. A seemingly important advantage of RACE over FAST-ED is that it was validated in the prehospital setting. Nevertheless, RACE appears too complex for prehospital EMS use, comprising a 5-item, 9-point assessment in which the decision to use or omit certain scale items (i.e. agnosia, aphasia) depends on the assumed involved hemisphere. 9 Indeed, during the validation phase, the scale was not performed in 40% of suspected stroke patients. 9 Although FAST-ED is based on the widely used FAST score and outperforms the NIHSS for prediction of LAVO in our database, it has potential drawbacks as it (a) imposes scoring a 'partial', 'mild' or 'moderate' deficit in most items, hampering interrater reliability; and (b) uses complex items (e.g. extinction/inattention) which are difficult for EMS personnel to assess. 13, 31 G-FAST seems more feasible for EMS use. However, in the original G-FAST study (i) vessel imaging modality to detect LAVO is unclear, and more importantly, (ii) definition of LAVO does not meet current clinical IAT-criteria (excluding ACA and M2 occlusion). 14 In our cohort, as expected, AF was more common in LAVO-patients. Although neither this nor other patient characteristics improved the group lasso model, the model including seven NIHSS-items had a higher AUROC (0.84) than the scales derived from the literature. Despite significant differences in performance of the scales, it should be pointed out that many of these differences are associated with small absolute differences in AUROC (i.e. 0.02). We accepted a small reduction in AUROC for the GACE decision tree (compared with the group lasso model), as we estimate that the prehospital feasibility is high since EMS personnel only has to take two steps to rule out transportation to a CSC for a substantial proportion of patients (61%, see Table 3 ), and only four for the remainder.
From a clinical perspective, it seems remarkable that facial asymmetry is such an important scoring item for GACE since it appears to have little localizing value. 32 It is important, however, to bear in mind that it is not this separate item, but the combination with gaze assessment that leads to a high predictive value for LAVO in our cohort.
In addition to LAVO prediction, allocation decision also depends on (1) the impact of delay on clinical efficacy of both IVT and IAT, (2) patient characteristics (e.g. medical history, time from symptom onset, course of the disease) and (3) logistic factors (e.g. urban/rural area, number of comprehensive and primary stroke centers (PSC) and distance to scene of stroke, interhospital distance, in-hospital door-to-needle and door-to-groin times). 33 Therefore, we chose to display ROCs, enabling determination of a clinically relevant cut-off point considering local circumstances.
Moreover, allocation decision highly depends on what kind of error one is willing to allow: (a) having more patients come to a CSC accepting that some of these may not have LAVO and incorrectly bypass a PSC delaying IVT (false-positives); or (b) being focused on only allocating LAVO-patients to a CSC accepting that some LAVO-patients will primarily be transported to a PSC without IAT-facilities (false-negatives). International Journal of Stroke, 14 (5) For example, a 75-year-old patient presenting with a partial gaze palsy, facial asymmetry, dysarthria and moderate left hemiparesis is assessed by EMS personnel 2.5 h after symptom onset. Scores for this patient on the best performing LAVO-prediction scales in our validation cohort are: RACE 4/9, FAST-ED 2/13 and G-FAST 4/4. When applying the original authors' cut-off point, the patient has a moderate to high chance of LAVO, advising direct transport to a CSC with G-FAST, and a transport to the nearest PSC with RACE and FAST-ED. These scales, however, do not take into account local circumstances.
Consider that a PSC is located 10 min-and a CSC 20 min from scene of stroke (with equal door-to-needle times). Bypassing the PSC is associated with a 10-min delay to IVT but a more substantial time delay to IAT is avoided by preventing inter-hospital transfer. Keeping in mind that IVT has limited efficacy in LAVO-patients, 25, [34] [35] [36] [37] [38] [39] a scale with a high sensitivity (such as G-FAST) seems the more desirable for this specific situation.
However, when transport time to a PSC is only 10 and to a CSC is 50 min, a scale with a high sensitivity is less desirable. Most patients (including false-positives) will then be transported to the CSC with a more substantial time delay to IVT (40 min) for non-LAVO patients and, in addition, overloading the CSC with a large volume of patients. Therefore, in this situation, a scale with a high specificity (such as RACE or FAST-ED) would probably be the more desired choice.
Overall, time is brain, but since LAVO-patients appear to clinically benefit more substantially from earlier IAT than overall stroke patients benefit from earlier IVT, 3,40 a moderate to high likelihood of LAVO seems to allow a fair time delay to IVT. How much delay exactly, however, remains complex, as logistics (which are dynamic as resources shift over time) determine the amount of accepted time delay at expense of the number of false-positively referred patients. To what extent implementation of a clinical LAVO-prediction scale affects local logistics and health care-related costs has to be estimated, since no formal cost-effectiveness analysis was performed.
Our study has several limitations. First, our study was performed retrospectively which could have led to selection bias. Data, however, were collected prospectively minimizing such an effect. Second, our cohort does not represent an unselected prehospital cohort. For example, ICHs were not included, leading to an artificially high prevalence of LAVO and IVT-treated patients, which could result in an overestimation of the prediction scales. To what extent this influences a decision to use a scale depends very much on local circumstances since ICHs are often concentrated in CSCs.
Of note, the retrospective nature and lack of an unselected cohort account for all LAVO-prediction scales included in our analysis and therefore do not diminish validity of between scale comparisons.
Finally, clinical scale assessment was performed in the in-hospital setting, rendering translation to the prehospital setting limited. Indeed, prospective validation in this setting is much warranted and our results should primarily be considered an important step towards a large prehospital prospective validation study which we planned to embed in the ongoing 'A Reduction in Time with Electronic Monitoring in Stroke' (ARTEMIS) trial conducted within three EMS regions, which allows patients to be electronically tracked from the first moment the dispatch office is alarmed up until start of reperfusion therapy (clinicaltrials.gov identifier: NCT02808806). 41 Nevertheless, clinical LAVO-detection could also be very helpful in order to optimize in-hospital logistics of potential IAT-eligible patients (e.g. pre-notification of neuro-interventional team and preparation of the angio suite can reduce door-to-groin times). 42 
Conclusion
We identified seven LAVO-prediction scales of which FAST-ED and RACE performed best and comparable to the NIHSS. An important limitation remains; however, that prospective validation in the prehospital EMS setting is lacking.
We developed a practical and easy-to-use decision tree that utilizes only two dichotomized NIHSS items for LAVO prediction for 61% of patients, and four items for the remaining patients in our cohort. Prospective validation of GACE in the prehospital setting is planned.
